Qualigen Therapeutics Past Earnings Performance
Past criteria checks 0/6
Qualigen Therapeutics's earnings have been declining at an average annual rate of -13.3%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 13.6% per year.
Key information
-13.3%
Earnings growth rate
27.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | -13.6% |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Qualigen Therapeutics GAAP EPS of -$0.11 beats by $0.06, revenue of $1.4M beats by $0.05M
Aug 16Qualigen Therapeutics files mixed shelf offering of up to $150M
Jul 29Qualigen partners Hande Sciences to support its application enabling studies for QN-302
Jul 06Can Qualigen Therapeutics (NASDAQ:QLGN) Afford To Invest In Growth?
Mar 08
We're A Little Worried About Qualigen Therapeutics' (NASDAQ:QLGN) Cash Burn Rate
Nov 23Is Qualigen Therapeutics (NASDAQ:QLGN) In A Good Position To Deliver On Growth Plans?
Apr 05Qualigen nabs additional U.S. patent for ALAN anticancer platform
Dec 15Qualigen Therapeutics EPS misses by $0.61, misses on revenue
Nov 13Revenue & Expenses BreakdownBeta
How Qualigen Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -12 | 6 | 5 |
| 30 Sep 23 | 5 | -18 | 9 | 7 |
| 30 Jun 23 | 6 | -18 | 11 | 6 |
| 31 Mar 23 | 6 | -18 | 11 | 6 |
| 31 Dec 22 | 0 | -14 | 10 | 4 |
| 30 Sep 22 | 1 | -15 | 11 | 14 |
| 30 Jun 22 | 5 | -16 | 12 | 11 |
| 31 Mar 22 | 4 | -17 | 12 | 11 |
| 31 Dec 21 | 6 | -18 | 12 | 11 |
| 30 Sep 21 | 5 | -7 | 12 | 0 |
| 30 Jun 21 | 5 | -12 | 11 | 0 |
| 31 Mar 21 | 5 | -25 | 10 | 0 |
| 31 Dec 20 | 4 | -20 | 8 | 0 |
| 30 Sep 20 | 5 | -28 | 6 | 0 |
| 30 Jun 20 | 5 | -20 | 4 | 0 |
| 31 Mar 20 | 6 | -2 | 2 | 0 |
| 31 Dec 19 | 5 | -1 | 1 | 0 |
| 31 Mar 19 | 6 | -1 | 1 | 0 |
| 31 Mar 18 | 10 | 0 | 2 | 0 |
Quality Earnings: QLGN is currently unprofitable.
Growing Profit Margin: QLGN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: QLGN is unprofitable, and losses have increased over the past 5 years at a rate of 13.3% per year.
Accelerating Growth: Unable to compare QLGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: QLGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: QLGN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.